Heiko Krissel

852 total citations
17 papers, 303 citations indexed

About

Heiko Krissel is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Heiko Krissel has authored 17 papers receiving a total of 303 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 6 papers in Cancer Research. Recurrent topics in Heiko Krissel's work include Colorectal Cancer Treatments and Studies (7 papers), Hepatocellular Carcinoma Treatment and Prognosis (5 papers) and Cancer, Lipids, and Metabolism (5 papers). Heiko Krissel is often cited by papers focused on Colorectal Cancer Treatments and Studies (7 papers), Hepatocellular Carcinoma Treatment and Prognosis (5 papers) and Cancer, Lipids, and Metabolism (5 papers). Heiko Krissel collaborates with scholars based in Germany, France and United States. Heiko Krissel's co-authors include Felix Kiecker, Dirk Schadendorf, Thomas Eigentler, Axel Hauschild, Katharina C. Kaehler, Claus Garbe, Selma Ugurel, Uwe Trefzer, Wilfried Eberhardt and Astrid Schott and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Heiko Krissel

17 papers receiving 298 citations

Peers

Heiko Krissel
Comparison fields: 5 of 36
  • Molecular Biology 183
  • Oncology 99
  • Hepatology 86
  • Pulmonary and Respiratory Medicine 73
  • Pathology and Forensic Medicine 70
Replace Yu Kataoka with:
Yu Kataoka Japan
Tao Osgood United States
Mally Romero United States
Tracy Lou United States
Eisuke Kurihara Japan
Nooreen Rubin United States
Oliver Schadt Germany
Leslie Hall United States
Xuejing Aimee Wang United States
Paul Swanson United States
Yu Kataoka Japan View profile →
Citations per field, relative to Heiko Krissel
Heiko Krissel · 1×
Citations per year, relative to Heiko Krissel
Heiko Krissel · 1×

Countries citing papers authored by Heiko Krissel

Since Specialization
Citations

This map shows the geographic impact of Heiko Krissel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heiko Krissel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heiko Krissel more than expected).

Fields of papers citing papers by Heiko Krissel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heiko Krissel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heiko Krissel. The network helps show where Heiko Krissel may publish in the future.

Co-authorship network of co-authors of Heiko Krissel

This figure shows the co-authorship network connecting the top 25 collaborators of Heiko Krissel. A scholar is included among the top collaborators of Heiko Krissel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Heiko Krissel. Heiko Krissel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
# Work Indexed citations
1
Radium-223 (Ra-223) versus novel antihormone therapy (NAH) for progressive metastatic castration-resistant prostate cancer (mCRPC) after 1 line of NAH: RADIANT, an international phase 4, randomized, open-label study.
2021 ·Journal of Clinical Oncology ·Karim Fizazi, Aranzazu González del Alba, (unknown), Iwona Skoneczna, Heiko Krissel, (unknown), Huanyu Chen, Volker Jean Wagner, Martin Boegemann
2
2
A randomized, double-blind, comparison of radium-223 and placebo, in combination with abiraterone acetate and prednisolone, in castration-resistant metastatic prostate cancer: subgroup analysis of Japanese patients in the ERA 223 study
2019 ·International Journal of Clinical Oncology ·Nobuaki Matsubara, Go Kimura, Hiroji Uemura, Hirotsugu Uemura, Motonobu Nakamura, Satoshi Nagamori, Atsushi Mizokami, Hiroaki Kikukawa, Makoto Hosono, Seigo Kinuya, Heiko Krissel, Jonathan Siegel, Yoshiyuki Kakehi
8
3
ERA 223: A phase III trial of radium-223 (Ra-223) in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients (pts) with bone-predominant metastatic castration-resistant prostate cancer (mCRPC)
2018 ·Annals of Oncology ·Mitchell R. Smith, Chris Parker, Fred Saad, K. Miller, Bertrand Tombal, Quan Sing Ng, Martin Bögemann, В. Б. Матвеев, Josep M. Piulats, Luis Eduardo Rosa Zucca, Axel Heidenreich, Yoshiyuki Kakehi, (unknown), Heiko Krissel, Jiayu Shen, (unknown), Celestia S. Higano
9
4
A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer
2015 ·Clinical Cancer Research ·Alex A. Adjei, Donald Richards, Anthony B. El-Khoueiry, Fadi Braiteh, (unknown), Joe Stephenson, Aram F. Hezel, Morris Sherman, Lawrence Garbo, (unknown), Cory Iverson, Jeffrey N. Miner, Zancong Shen, Li‐Tain Yeh, (unknown), David M. Wilson, Kimberly J. Manhard, Prabhu Rajagopalan, Heiko Krissel, Neil J. Clendeninn
16
5
Abstract 5252: Liquid biopsies to prospectively select patients with KRAS or NRAS mutant hepatocellular carcinoma (HCC) in two phase II studies with Refametinib
2015 ·Cancer Research ·Heiko Krissel, (unknown), (unknown), (unknown), (unknown), Fabrício Henrique Pereira De Souza, (unknown), Kathleen Schostack, Joachim Reischl, Philipp Angenendt, Barrett H. Childs, Michael Teufel
1
6
A Phase II Study of the Efficacy and Safety of the Combination Therapy of the MEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma
2014 ·Clinical Cancer Research ·Ho Yeong Lim, Jeong Heo, Hye Jin Choi, Cheng-Yao Lin, Jung‐Hwan Yoon, Chiun Hsu, Kun‐Ming Rau, Ronnie T. P. Poon, Winnie Yeo, Joong‐Won Park, Miah Hiang Tay, Wen-Son Hsieh, Christian Kappeler, Prabhu Rajagopalan, Heiko Krissel, Michael Jeffers, Chia‐Jui Yen, Won Young Tak
86
7
Dynamic Contrast-Enhanced MRI Parameters as Biomarkers for the Effect of Vatalanib in Patients with Non-Small-Cell Lung Cancer
2014 ·Future Oncology ·Felix Nensa, Jörg Stattaus, Bruno Morgan, Mark A. Horsfield, Jean‐Charles Soria, Benjamin Besse, V. Gounant, Antoine Khalil, (unknown), B. Fischer, Heiko Krissel, Dirk Laurent, Daniel C. Christoph, Wilfried Eberhardt, Thomas Gauler
9
8
Regorafenib (REG) in patients with hepatocellular carcinoma (HCC) progressing following sorafenib: An ongoing randomized, double-blind, phase III trial.
2013 ·Journal of Clinical Oncology ·Ann‐Lii Cheng, Richard S. Finn, Masatoshi Kudo, Josep M. Llovet, Shukui Qin, Marie‐Aude Le Berre, Heiko Krissel, Jordi Bruix
1
9
A phase II trial of MEK inhibitor BAY 86-9766 in combination with sorafenib as first-line systemic treatment for patients with unresectable hepatocellular carcinoma (HCC).
2012 ·Journal of Clinical Oncology ·Ho Yeong Lim, Chia‐Jui Yen, Won Young Tak, Jeong Heo, Hye Jin Choi, Cheng-Yao Lin, Jung‐Hwan Yoon, Chiun Hsu, Kun‐Ming Rau, Ronnie T.P. Poon, Winnie Yeo, Joong‐Won Park, Miah Hiang Tay, Kuangwen Hsieh, Christian Kappeler, Prabhu Rajagopalan, Heiko Krissel
14
10
Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC)
2011 ·Annals of Oncology ·Thomas Gauler, Benjamin Besse, Audrey Mauguen, Jean‐Baptiste Méric, V. Gounant, B. Fischer, Tobias R. Overbeck, Heiko Krissel, Dirk Laurent, Marjaana Tiainen, Frédéric Commo, Jean‐Charles Soria, Wilfried Eberhardt
24
11
140 Combination of PI3K inhibitor BAY 80-6946 and allosteric MEK inhibitor BAY 86-9766 (RDEA119), a promising approach for the treatment of colorectal cancers
2010 ·European Journal of Cancer Supplements ·(unknown), Andrea Haegebarth, Florian Puehler, (unknown), Jens Hoffmann, (unknown), Heiko Krissel, (unknown), Dominik Mumberg, Karl Ziegelbauer
1
12
Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma
2008 ·Melanoma Research ·Axel Hauschild, Uwe Trefzer, Claus Garbe, Katharina C. Kaehler, Selma Ugurel, Felix Kiecker, Thomas Eigentler, Heiko Krissel, Astrid Schott, Dirk Schadendorf
69
13
C1-01: Phase II open-label study to investigate PTK787/ZK 222584 (PTK/ZK) orally administered as a second-line monotherapy in patients with stage IIIB or stage IV non-small-cell lung cancer (NSCLC)
2007 ·Journal of Thoracic Oncology ·Thomas Gauler, Benjamin Besse, Jean‐Baptiste Méric, V. Gounant, (unknown), Tobias R. Overbeck, Heiko Krissel, Dirk Laurent, Jean‐Charles Soria, Wilfried Eberhardt
2
14
Phase II open-label study to investigate efficacy and safety of PTK787/ZK 222584 (PTK/ZK) orally administered once daily or twice daily at 1,250 mg as second-line monotherapy in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC)
2007 ·Journal of Clinical Oncology ·Thomas Gauler, Benjamin Besse, Jean‐Baptiste Méric, V. Gounant, Bruce S. Fischer, Tobias R. Overbeck, Heiko Krissel, Dirk Laurent, Jean‐Charles Soria, Wilfried Eberhardt
25
15
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) as a biomarker for the effect of PTK787/ZK 222584 (PTK/ZK) as second-line mono-therapy in patients with stage IIIB or stage IV non-small cell lung cancer (NSCLC)
2007 ·Journal of Clinical Oncology ·Bruno Morgan, Mark A. Horsfield, J. Stattaus, (unknown), Thomas Gauler, V. Gounant, Bruce S. Fischer, Dirk Laurent, Heiko Krissel, Wilfried Eberhardt
8
16
Phase II open-label study to investigate efficacy and safety of PTK787/ZK 222584 orally administered once daily at 1,250 mg as second-line monotherapy in patients (pts) with stage IIIB or stage IV non-small cell lung cancer (NSCLC)
2006 ·Journal of Clinical Oncology ·Thomas Gauler, Bruce S. Fischer, Jean‐Charles Soria, V. Gounant, Frank Griesinger, Heiko Krissel, Dirk Laurent, Wilfried Eberhardt
12
17
A phase II multicenter study on the histone deacetylase (HDAC) inhibitor MS-275, comparing two dosage schedules in metastatic melanoma
2006 ·Journal of Clinical Oncology ·Axel Hauschild, Uwe Trefzer, Claus Garbe, Katharina C. Kaehler, Selma Ugurel, Felix Kiecker, Thomas Eigentler, Heiko Krissel, Dirk Schadendorf
16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yu Kataoka Breakdown of academic impact, for papers by Tao Osgood Breakdown of academic impact, for papers by Mally Romero Breakdown of academic impact, for papers by Tracy Lou Breakdown of academic impact, for papers by Eisuke Kurihara Breakdown of academic impact, for papers by Nooreen Rubin Breakdown of academic impact, for papers by Oliver Schadt Breakdown of academic impact, for papers by Leslie Hall Breakdown of academic impact, for papers by Xuejing Aimee Wang Breakdown of academic impact, for papers by Paul Swanson
Rankless by CCL
2026